Blueprint Medicines

About:

Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.

Website: http://www.blueprintmedicines.com

Twitter/X: blueprintmeds

Top Investors: RA Capital Management, Royalty Pharma, Wellington Management, F-Prime Capital, Perceptive Advisors

Description:

Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data revolution: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.